Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


Testing IDs Actionable Drivers in Up to Two-Thirds of Lung Cancers
Patients receiving targeted drugs based on molecular drivers lived longer
This article is older than one year and is no longer available.

Copyright © 2014 HealthDay. All rights reserved.

July 30, 2015

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

New Rx for Myeloid Malignancies Moves to Phase II Clinical Trials

Novel Microendoscope Ups Accuracy of Esophageal Screening

RAPID Score Validated for Prognosis of Pleural Infections

Patients Report Improved Care Access, Better Health With ACA

Outcomes Equal for Continuous, Intermittent β-Lactams in Sepsis

2015 MOC Program Expected to Cost $5.7 Billion Over 10 Years